NBS 10

Drug Profile

NBS 10

Alternative Names: AMR-001; CLBS 10; NBS10

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amorcyte
  • Developer Caladrius Biosciences
  • Class Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Brain injuries
  • Discontinued Myocardial infarction

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Brain injuries in USA (Parenteral)
  • 15 Mar 2016 Caladrius out-licenses CD34 ischemic repair technnology to SPS Cardio LLC
  • 18 Dec 2015 NBS 10 is available for licensing as of 18 Dec 2015. http://www.caladrius.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top